Slide 1: Exchange filing cover letter for investor presentation
10th February, 2023 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code
Slide 2: Quarter ended December 31st, 2022
Quarter ended December 31st, 2022 February 2023
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) 21,407 EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 16,948 4,976 3,400 4,453 3,937 2,538 24.3% 26.8% 2,744 26.3% 18.4% 14.3% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22^ FY18 FY19
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q3 FY23 Result Highlights
Q3 FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 6,140 6,398 5,621 1,149 1,095 823 19.5% 18.0% 13.4% Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹) 6.3 5.7 10.8% 606 983 5.7% 4.1 893 1.6% 367 648 98 Q3FY22 Q2FY23
Slide 9: 9M FY23 Result Highlights
9M FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 17,944 3,094 2,876 15,717 19.7% 16.0% 9MFY22 9MFY23 9MFY22 9MFY23 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 17.2 9.5% 2,698 14.2 2,230 1,499 3.9% 700 9MFY22 9MFY23 9MFY22 9MFY23 *EBITDA excluding oth
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q3 FY23 Q3 FY22 YoY % 9M FY23 9M FY22 YoY% Income from Operations (Net) 6,397.9 5,620.8 13.8% 17,943.6 15,717.0 14.2% COGS 788.1 1,288.3 -38.8% 3,320.1 2,997.0 10.8% Employee Expenses 2,702.3 2,550.8 5.9% 7,799.4 7,289.0 7.0% Other Expenses 1,758.8 686.7
Slide 11: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenues (₹ mn) Q3 FY23 Q3 FY22 YoY % 9M FY23 9M FY22 YoY% FY22 CARBOGEN AMCIS - Contract Research 4,623.0 4,215.3 9.7% 12,641.7 10,897.0 16.0% 14,896.6 & Manufacturing Services1 CARBOGEN AMCIS- Cholesterol & Vit D 825.1 543.3 51.9% 2,103.0 2,429.2 -13.4% 3,061.5 Analogues2
Slide 12: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q3 FY23 Total Operating Revenue – 9M FY23 DCAL India - NCE APIs & Intermediates 7.1% 12.9% 7.2% 15.5% DCAL India - Quats & Generics 8.1% 7.6% CARBOGEN AMCIS - Contract Research & Manufacturing 72.3% Services 69.3% CARBOGEN AMCIS - Cholesterol & Vit D Analog
Slide 13: Margin Analysis
MARGIN ANALYSIS EBITDA Margin % Q3 FY23 Q3 FY22 9M FY23 9M FY22 FY22 CARBOGEN AMCIS - Contract Research & 22.3% 20.0% 18.8% 20.1% 18.2% Manufacturing Services1 CARBOGEN AMCIS - Cholesterol & Vit D 17.1% 30.5% 18.1% 30.4% 30.2% Analogues2 DCAL India - NCE APIs & Intermediates3 -$ -@ 0.2% 1.8%@ - DCAL
Slide 14: Q3 & 9M FY23 Result Highlights
Q3 & 9M FY23 RESULT HIGHLIGHTS Net Revenue at Rs 6,397.9 mn in Q3 FY23 up by 13.8% YoY due to increased revenue at all entities and across all segments due to strong demand and healthy order book. COGS was lower by 38.8% due to higher sales of late Phase III molecules, including validation batches.
Slide 15: Operational Changes – Naroda Unit I
OPERATIONAL CHANGES – NARODA UNIT - I Addition of other 2 reactors: 1) 10KL SS (this is allowing to increase the batch size of several products increasing the productivity per year. Additionally allows double trains for certain products). 2) 4KL GLR: this allows more multipurpose products because of
Slide 16: Operational Changes – Naroda Unit II
OPERATIONAL CHANGES – NARODA UNIT - II Complete refurbishment of the bonded warehouse. Introduced RLAF for sampling. Flooring completely re-done. Material was reallocated allowing only material related to U2. One part of the warehouse which was used for U1 is now used for U2. Washing area modified.
Slide 17: Operational Changes – Bavla
OPERATIONAL CHANGES – BAVLA Brand new Intermediate warehouse for 2-8 degree C. Intermediate warehouse was also added with RLAF for sampling/dispensing. BSR was added with a RLAF for sampling and dispensing of finished products. This is a major improvement GMP wise and operational wise because it doe
Slide 18: Company Overview
COMPANY Dishman Carbogen Amcis
Slide 19: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 20: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 21: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 22: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 23: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES ▪ Focus is on supporting the development process from bench to market ▪ Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 24: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 25: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY22 FY22 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 24
Slide 26: Industry Overview
INDUSTRY Dishman Carbogen Amcis
Slide 27: Top 20 Therapy Areas (US$ bn) - 2026
2026 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2026 5-Yr CAGR 2021-2025 Oncologics 306 9-12% Immunology 178 6-9% Top 20 Therapy Areas (US$ bn) - 2026 Antidiabetics 173 6-9% Neurology 151 3-6% Cardiovascular 87 4-7% Antic
Slide 28: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 27 Sourc
Slide 29: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Mr. Binay Sarda Global CFO Ernst & Young LLP Email: harshil.dalal@dishmangroup.com P: +91 9920893764 Email: binay.sarda@in.ey.com